The LELANTOS-1 study has enrolled patients with non-ambulatory DMD. Credit: ChiccoDodiFC/Shutterstock.com.

FibroGen’s Phase III LELANTOS-1 clinical study of pamrevlumab has failed to meet the primary endpoint of Performance of the Upper Limb 2.0 (PUL 2.0) score at week 52, compared to baseline, for Duchenne Muscular Dystrophy (DMD).

The double-blind, global, randomised LELANTOS-1 study has enrolled 99 patients with non-ambulatory DMD aged 12 years and above to assess the safety and efficacy of pamrevlumab, along with systemic corticosteroids, against a placebo.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Pamrevlumab was found to be well tolerated and safe, with mild or moderate treatment emergent adverse events.

FibroGen CEO Enrique Conterno said: “While disappointed with these results, we look forward to sharing the data at a future medical conference to contribute towards the understanding of this devastating disease.

“FibroGen would like to thank the patients, caregivers, and clinical trial investigators for their dedication in participating in this study.”

See Also:

LELANTOS-1 is a part of FibroGen’s Phase III clinical development programme of pamrevlumab for DMD, which also includes LELANTOS-2.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The fully enrolled LELANTOS-2 study has evaluated the safety and efficacy of pamrevlumab, combined with systemic corticosteroids, in patients with ambulatory DMD.

Topline data from the Phase III LELANTOS-2 study is anticipated in the third quarter of this year.

The company is developing the anti-CTGF human monoclonal antibody, pamrevlumab, for treating metastatic pancreatic cancer, locally advanced unresectable pancreatic cancer, and idiopathic pulmonary fibrosis.

Last month, FibroGen reported positive topline results from the Chinese Phase III trial of roxadustat for the treatment of chemotherapy induced anaemia.